

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司
Shandong Xinhua Pharmaceutical Company Limited
(a joint stock limited company established
in the People's Republic of China with limited liability)
(Stock Code: 0719)

**TWO CONTINUING CONNECTED TRANSACTIONS, ANNUAL CAPS AND
RATIFICATION OF PREVIOUS CONTINUING CONNECTED TRANSACTION
AND PROPOSED ANNUAL CAPS**

Reference is made to the announcement of the Company dated 5 September 2008.

A. Two continuing connected transactions

1. Continuing connected transactions between the Company and L. Perrigo

The Board announces that on 7 October 2008, the Company and L. Perrigo entered into the Perrigo Agreement in relation to the Company supplying pharmaceutical products to L. Perrigo and its affiliates for a period of two years from 1 January 2008 to 31 December 2009.

The term of the Perrigo Agreement runs from 1 January 2008 to 31 December 2009 and is automatically renewable for a term of one year unless terminated on six months' written notice.

L. Perrigo is a subsidiary of Perrigo Company. Perrigo Company is a connected person of the Company as it is the parent company of Perrigo International, which is a substantial shareholder of Xinhua Perrigo, a 50.1% owned subsidiary of the Company. Accordingly, L. Perrigo, being a subsidiary of Perrigo Company, is also a connected person of the Company and the transactions contemplated under the Perrigo Agreement constitute continuing connected transactions under the Listing Rules.

The highest annual cap for 2008, 2009 and 2010 under the Perrigo Agreement is RMB88,000,000. The applicable percentage ratios (as defined in the Listing Rules) exceed 2.5% on an annual basis and the total consideration exceeds HK\$10,000,000. In accordance with rules 14A.35(3) and (4) of the Listing Rules, the Company requires independent shareholders' approval for entering into the Perrigo Agreement as described in rule 14A.48, and must comply with the reporting requirements as described in rules 14A.45 to 14A.47 of the Listing Rules.

2. Continuing connected transactions between the Company and Eastwest

The Board announces that on 9 October 2008, the Company and Eastwest entered into the Eastwest Agreement in relation to the Company supplying pharmaceutical products to Eastwest for a period of two years from 1 January 2008 to 31 December 2009.

As at the date of this announcement, Eastwest is a substantial shareholder of Xinhua Eastwest, a subsidiary of the Company, and therefore Eastwest is a connected person of the Company. As a result, the ongoing transactions between the Company and Eastwest constitute continuing connected transactions under Chapter 14A of the Listing Rules.

The higher annual cap for 2008 and 2009 under the Eastwest Agreement is RMB12,000,000. The applicable percentage ratios (as defined in the Listing Rules) exceed 2.5% on an annual basis and the total consideration exceeds HK\$10,000,000. In accordance with rules 14A.35(3) and (4) of the Listing Rules, the Company requires independent shareholders' approval for entering into the Eastwest Agreement as described in rule 14A.48, and must comply with the reporting and announcement requirements as described in rules 14A.45 to 14A.47 of the Listing Rules.

B. Ratification of the continuing connected transactions conducted in 2007 and 2008

As disclosed in the announcement of the Company dated 5 September 2008, the Company conducted continuing connected transactions with Perrigo Company in 2007 and first half of 2008 and XPIE, a subsidiary of the Company, also conducted continuing connected transactions with Perrigo Company in 2007 without prior independent shareholders' approval.

When these two continuing connected transactions in 2007 are aggregated, the applicable percentage ratios (as defined in the Listing Rules) exceeded 2.5% on an annual basis and the total consideration exceeded HK\$10,000,000. To comply with the independent shareholders' approval requirements described in rule 14A.48 of the Listing Rules, the Company will seek ratification from independent shareholders in relation to the two continuing connected transactions in 2007 at the EGM.

Further, as disclosed in the announcement dated 5 September 2008, from 1 January 2008 to 30 June 2008 there were continuing connected transactions between the Company and Perrigo Company but there were no transactions between XPIE and Perrigo Company. The applicable percentage ratios (as defined in the Listing Rules) were slightly below 2.5% for the six months' period. In accordance with rule 14A.34(1) of the Listing Rules, the Company is only required to comply with the reporting and announcement requirements as described in rules 14A.45 to 14A.47 of the Listing Rules and is exempt from the independent shareholders' approval requirements.

However, the Company has been continuing to conduct these connected transactions with Perrigo Company from 1 July 2008 to the date of EGM and it is not clear whether the applicable percentage ratios for whole year of 2008 will exceed 2.5%, therefore, to be prudent, the Company will also seek ratification from the independent shareholders' approval on the continuing connected transactions between the Company and Perrigo Company in 2008 at the EGM.

Since the Perrigo Agreement covers the transactions between the Company and L. Perrigo or L. Perrigo's affiliates, if the Company enters into any transactions with L. Perrigo or Perrigo Company under the period of the Perrigo Agreement, no separate independent shareholders' approval is required once the Perrigo Agreement and the proposed annual caps are approved by the independent shareholders at the EGM.

The Company has complied with the reporting requirements earlier this year and published an announcement on 5 September 2008.

C. Annual caps for the continuing connected transactions between Xinhua Perrigo and Perrigo China Business Trust

As disclosed in the announcement of the Company dated 5 September 2008, before Perrigo Company became a connected person of the Company on 1 January 2007, Xinhua Perrigo, then an associated company of the Company, and Perrigo China Business Trust, a subsidiary of Perrigo Company, entered into the Perrigo China Agreement dated 3 July 2006 for a period of 10 years. It was also stated in the above

announcement that the Company would fix annual caps for the continuing connected transactions.

However, pursuant to rule 14A.41 of the Listing Rules, since there has been no variation or renewal of the agreement, Xinhua Perrigo only has to comply with the applicable reporting and disclosure requirements of Chapter 14A of the Listing Rules and no independent shareholders' approval for the continuing connected transactions and no annual caps are required.

The Company has complied with the reporting requirements earlier this year and published an announcement on 5 September 2008.

D. Independent Board Committee

An Independent Board Committee has been formed to advise the independent shareholders in connection with the following:-

1. Perrigo Agreement and the proposed annual caps;
2. Eastwest Agreement and the proposed annual caps; and
3. ratification of the continuing connected transactions between the Company and Perrigo Company in 2007 and 2008, and between XPIE and Perrigo Company in 2007.

A circular containing, among other things, (i) details of the Perrigo Agreement and Eastwest Agreement; (ii) a letter from the Independent Board Committee to the Shareholders; (iii) the recommendations of the independent financial adviser; and (iv) a notice of EGM to approve among other things, the Perrigo Agreement and Eastwest Agreement and the respective annual caps, and to ratify the continuing connected transactions between the Company and Perrigo Company in 2007 and 2008, and between XPIE and Perrigo Company in 2007 will be dispatched to the Shareholders as soon as practicable.

A. TWO CONTINUING CONNECTED TRANSACTIONS

1. Continuing connected transactions between the Company and L. Perrigo

Perrigo Agreement

Date : 7 October 2008

Parties : (i) the Company
(ii) L. Perrigo

Principal terms and conditions

On 7 October 2008, the Company and L. Perrigo entered into the Perrigo Agreement in relation to the Company supplying the pharmaceutical products to L. Perrigo and its affiliates, including Perrigo Company.

The term of the Perrigo Agreement runs from 1 January 2008 to 31 December 2009 and is automatically renewable for a term of one year unless terminated on six months' written notice.

Payment terms

1. The price of the pharmaceutical products is based on market prices.
2. L. Perrigo shall pay the Company within 60 days after invoicing.

Proposed annual caps

The proposed annual caps for the Perrigo Agreement are as follows:-

	2008 (RMB ‘000)	2009 (RMB ‘000)	2010* (RMB ‘000)
Proposed annual caps	48,000	80,000	88,000

* if the agreement is renewed

The Company has determined the above annual caps based on the following factors:-

- (a) the historical figures in 2007 and January – June 2008 for the transactions between the Company and Perrigo Company, the parent company of L. Perrigo (please see Table 1 below);
- (b) the demand set out by L. Perrigo; and
- (c) the increase in the market prices of chemical raw materials for the production of the pharmaceutical products (please see Table 2 below).

Table 1- Historical figures in 2007 and January – June 2008 for the transactions between the Company and Perrigo Company, the parent company of L. Perrigo

	2007 (RMB’000)	1 January 2008 to 30 June 2008 (RMB’000)
Total consideration	45,619	26, 393

Table 2 - Approximate Market prices of chemical raw materials

	January 2007	June 2008
Sulphuric acid	RMB370 per ton	RMB1,700 per ton
Dimethyl sulphate	RMB2,500 per ton	RMB5,000 per ton
Reductant	RMB500 per ton	RMB1,500 per ton

Reasons for and benefits of the continuing connected transactions between the Company and L. Perrigo

By selling the pharmaceutical products to L. Perrigo, the Company is able to expand its business in the United States. The Directors consider that the transactions have been negotiated on an arm’s length basis and are on normal commercial terms. They also consider that the terms of the transactions are fair and reasonable, and that entering into the transactions is in the best interests of the shareholders as a whole.

Connected Relationship

L. Perrigo is a subsidiary of Perrigo Company. Perrigo Company is a connected person of the Company as it is the parent company of Perrigo

International, which is a substantial shareholder of Xinhua Perrigo, a 50.1% owned subsidiary of the Company. Accordingly, L. Perrigo, being a subsidiary of Perrigo Company, is also a connected person of the Company and the transactions contemplated under the Perrigo Agreement constitute continuing connected transactions under the Listing Rules.

Implications under the Listing Rules

The highest annual cap for 2008, 2009 and 2010 under the Perrigo Agreement is RMB88,000,000. The applicable percentage ratios (as defined in the Listing Rules) exceed 2.5% on an annual basis and the total consideration exceeds HK\$10,000,000. In accordance with rules 14A.35(3) and (4) of the Listing Rules, the Company requires independent shareholders' approval as described in rule 14A.48, and must comply with the reporting and announcement requirements as described in rules 14A.45 to 14A.47 of the Listing Rules.

Information about the Company and L. Perrigo

The Company is principally engaged in the development, manufacture and sales of bulk pharmaceuticals, preparations and chemical products.

L. Perrigo is principally engaged in the manufacture, distribution and sale of certain over-the-counter, non-prescription pharmaceutical products in the United States.

2. Continuing connected transactions between the Company and Eastwest

Eastwest Agreement

Date : 9 October 2008

Parties : (i) the Company
(ii) Eastwest

Principal terms and conditions

The Company and Eastwest entered into the Eastwest Agreement in relation to the Company supplying the pharmaceutical products to Eastwest for a period of two years from 1 January 2008 to 31 December 2009.

Payment terms

1. The price of the pharmaceutical products is based on the prevailing market price.
2. Eastwest shall pay the Company within the time specified at the time of entering into the transactions.

Proposed annual caps

The proposed annual caps for the Eastwest Agreement are as follows:-

	2008 (RMB '000)	2009 (RMB '000)
Proposed annual caps	8,000	12,000

The Company has determined the above annual caps based on the following factors:-

- (a) the historical figures in 2007 and January – June 2008 for the transactions

between the Company and Eastwest (please see Table 3 below);

- (b) the demand by Eastwest; and
- (c) the increase in the market prices of chemical raw materials for the production of the pharmaceutical products (please see Table 2 above).

Table 3- Historical figures in 2007 and January – June 2008 for the transactions between the Company and Eastwest

	2007 (RMB'000)	1 January 2008 to 30 June 2008 (RMB'000)
Total consideration	5,276	2,160

Reasons for and benefits of the continuing connected transactions between the Company and Eastwest

By selling the pharmaceutical products to Eastwest, the Company is able to expand its business in the United States. The Directors consider that the transactions were and are on normal commercial terms and in the ordinary course of business. They also consider that the terms of the transactions were and are fair and reasonable and that entering into the transaction is in the interests of the Shareholders as a whole.

Connected Relationship

As at the date of this announcement, Eastwest is a substantial shareholder of Xinhua Eastwest, a subsidiary of the Company, and therefore Eastwest is a connected person of the Company. As a result, the ongoing transactions between the Company and Eastwest constitute continuing connected transactions under Chapter 14A of the Listing Rules.

Implications under the Listing Rules

The higher annual cap for 2008 and 2009 under the Eastwest Agreement is RMB12,000,000. One of the applicable percentage ratios (as defined in the Listing Rules) exceeds 2.5% on an annual basis and the total consideration exceeds HK\$10,000,000. In accordance with rule 14A.35(3) and (4) of the Listing Rules, the Company requires independent shareholders' approval as described in rule 14A.48, and must comply with the reporting and announcement requirements as described in rules 14A.45 to 14A.47 of the Listing Rules.

Information about Eastwest

Eastwest is principally engaged in trading business.

B. RATIFICATION OF THE CONTINUING CONNECTED TRANSACTIONS CONDUCTED IN 2007 AND 2008

As disclosed in the announcement of the Company dated 5 September 2008, the Company conducted continuing connected transactions with Perrigo Company in 2007 and the first half of 2008 and XPIE also conducted continuing connected transactions with Perrigo Company in 2007 without independent shareholders' prior approval.

1. Continuing connected transactions between the Company and Perrigo Company

Principal terms and conditions and consideration

From 1 January 2007 to 31 December 2007, the Company and Perrigo Company entered into various transactions in relation to the Company selling pharmaceutical products to Perrigo Company for the total consideration of RMB45,619,000.

From 1 January 2008 to the date of this announcement, the Company and Perrigo Company have continued the above transactions. The total consideration for the first half of 2008 is RMB26,393,000.

The Directors believe that the consideration of each connected transaction for the relevant period in 2007 and 2008 was arrived at after arm's length negotiations between the parties thereto on normal commercial terms. The consideration of each connected transaction was based on the prevailing market price.

Payment terms

The consideration for the various transactions between the Company and Perrigo Company was paid by Perrigo Company in cash to the Company within 30 days from the date of delivery of goods in each transaction.

Reasons for and benefits of the continuing connected transactions between the Company and Perrigo Company

By selling the pharmaceutical products to Perrigo Company, the Company was able to expand its business in the pharmaceutical industry in the United States. The Directors consider that the transactions were negotiated on an arm's length basis and were on normal commercial terms and in the ordinary course of business. They also consider that the terms of the transactions are fair and reasonable, and that entering into the transactions was and is in the best interests of the shareholders as a whole.

Connected Relationship

Prior to 1 January 2007, each of the Company and Perrigo International held a 50% equity interest in Xinhua Perrigo. Accordingly, Xinhua Perrigo was not a subsidiary of the Company and Perrigo International was not a connected person of the Company. On 1 January 2007, the Company acquired a 0.1% equity interest in Xinhua Perrigo and Xinhua Perrigo became a subsidiary of the Company. Accordingly, Perrigo International, as a substantial shareholder of Xinhua Perrigo, then became a connected person of the Company. Perrigo Company, the parent company of Perrigo International, also became a connected person of the Company on 1 January 2007. As a result, the ongoing transactions between the Company and Perrigo Company in 2007 and 2008 constituted continuing connected transactions under Chapter 14A of the Listing Rules

2. Continuing connected transactions between XPIE and Perrigo Company

Principal terms and conditions and consideration

From 1 January 2007 to 31 December 2007, XPIE entered into various transactions with Perrigo Company in relation to XPIE selling pharmaceutical products to Perrigo Company for a total consideration of RMB9,752,000.

From 1 January 2008 to the date of this announcement, XPIE and Perrigo Company have not conducted any transactions.

The consideration of each connected transaction in 2007 was arrived at after arm's length negotiations between the parties thereto on normal commercial terms. The consideration of each connected transaction was based on the prevailing market price.

Payment terms

The consideration for the various sales contracts between XPIE and Perrigo Company was paid by Perrigo Company in cash to XPIE within 30 days from the date of delivery of the goods in each transaction.

Reasons for and benefits of the continuing connected transactions between XPIE and Perrigo Company

By selling the pharmaceutical products to Perrigo Company through XPIE, the Company was able to expand its business in the pharmaceutical industry in the United States. The Directors consider that the transactions were negotiated on an arm's length basis and were on normal commercial terms and in the ordinary course of business. They also consider that the terms of the transactions were fair and reasonable, and the entering into the transactions was and is in the best interests of the shareholders as a whole.

Connected Relationship

The Company indirectly held and holds a 98% equity interest in XPIE. Therefore, XPIE was and is a subsidiary of the Company. As mentioned in paragraph B.1 above, Perrigo International became a connected person of the Company on 1 January 2007. Accordingly, Perrigo Company, the parent company of Perrigo International, also became a connected person of the Company on 1 January 2007. As a result, the ongoing transactions between XPIE and Perrigo Company in 2007 constituted continuing connected transactions under Chapter 14A of the Listing Rules.

Implications under the Listing Rules for the above two continuing connected transactions

Pursuant to rules 14A.25 and 14A.26 of the Listing Rules, the continuing connected transactions between the Company and Perrigo Company, and the continuing connected transactions between XPIE and Perrigo Company could be aggregated as they are the transactions of the same nature entered into by the Company or its subsidiaries with the same party i.e., Perrigo Company.

When the two continuing connected transactions between the Company and Perrigo Company and between XPIE and Perrigo Company in 2007 are aggregated, the applicable percentage ratios (as defined in the Listing Rules) exceeded 2.5% on an annual basis and the total consideration exceeded HK\$10,000,000. In accordance with rules 14A.35(3) and (4) of the Listing Rules, the Company required independent shareholders' approval as described in rule 14A.48 of the Listing Rules, and must comply with the reporting and announcement requirements as described in rules 14A.45 to 14A.47 of the Listing Rules.

To comply with the independent shareholders' approval requirements described in rule 14A.48 of the Listing Rules, the Company will seek ratification from independent shareholders in relation to the two continuing connected transactions in 2007 at the EGM.

Further, as disclosed in the announcement dated 5 September 2008, from 1 January 2008 to 30 June 2008 there were continuing connected transactions between the Company and Perrigo Company but there were no transactions between XPIE and Perrigo Company. The applicable percentage ratios (as defined in the Listing Rules) were slightly below 2.5% for this six months' period. In accordance with rule 14A.34(1) of the Listing Rules, the Company is only required to comply with the reporting and announcement requirements as described in rules 14A.45 to 14A.47 of the Listing Rules and is exempt from the independent shareholders' approval requirements.

However, the Company has been continuing to conduct these connected transactions

with Perrigo Company from 1 July 2008 to the date of EGM and it is not clear whether the applicable percentage ratios for whole year of 2008 will exceed 2.5%, and therefore, to be prudent, the Company is also seeking ratification from the independent shareholders' on the continuing connected transactions between the Company and Perrigo Company in 2008 at the EGM

Since the Perrigo Agreement covers the transactions between the Company and L. Perrigo or L. Perrigo's affiliates, if the Company enters into any transactions with L. Perrigo or Perrigo Company under the period of the Perrigo Agreement, no separate independent shareholders' approval is required once the Perrigo Agreement and the proposed annual caps are approved by the independent shareholders at the EGM.

The Company has complied with the reporting requirements earlier this year and published an announcement on 5 September 2008.

Information about Perrigo Company and XPIE

Perrigo Company is principally engaged in the manufacture, distribution and sale of certain over-the-counter, non-prescription pharmaceutical products in the United States of America.

XPIE is principally engaged in import and export of chemical products and pharmaceutical technical know-how in the PRC.

C. ANNUAL CAPS FOR THE CONTINUING CONNECTED TRANSACTIONS BETWEEN XINHUA PERRIGO AND PERRIGO CHINA BUSINESS TRUST

As disclosed in the announcement of the Company dated 5 September 2008, before Perrigo Company became a connected person of the Company on 1 January 2007, Xinhua Perrigo, then an associated company of the Company, and Perrigo China Business Trust, a subsidiary of Perrigo Company, entered into the Perrigo China Agreement dated 3 July 2006 for a period of 10 years. It was also stated in the above announcement that the Company would fix annual caps for the continuing connected transactions.

Rule 14A.41 requirements

However, pursuant to rule 14A.41 of the Listing Rules, since there has been no variation or renewal of the agreement, Xinhua Perrigo only has to comply with the applicable reporting and disclosure requirements of Chapter 14A of the Listing Rules and no independent shareholders' approval for the continuing connected transactions and no annual caps are required.

The Company has complied with the reporting requirements earlier this year and published an announcement on 5 September 2008.

Connected Relationship

As mentioned in paragraphB.1 above, Perrigo Company was and is a connected person of the Company. Therefore, Perrigo China Business Trust, a subsidiary of Perrigo Company, also was and is a connected person of the Company and its subsidiaries. As Xinhua Perrigo became a subsidiary of the Company on 1 January 2007, the ongoing transactions between the Xinhua Perrigo and Perrigo China Business Trust became continuing connected transactions under Chapter 14A of the Listing Rules.

Information about Xinhua Perrigo and Perrigo China Business Trust

Xinhua Perrigo is principally engaged in the production of medicine and medical products in the PRC.

Perrigo China Business Trust is principally engaged in the sourcing of active pharmaceutical ingredients for sale to other entities producing pharmaceutical

products in the United States.

D. Independent Board Committee

An Independent Board Committee has been formed to advise the independent shareholders in connection with the following:-

1. Perrigo Agreement and the proposed annual caps;
2. Eastwest Agreement and the proposed annual caps; and
3. ratification of the continuing connected transactions between the Company and Perrigo Company in 2007 and 2008, and between XPIE and Perrigo Company in 2007.

A circular containing, among other things, (i) details of the Perrigo Agreement and Eastwest Agreement; (ii) a letter from the Independent Board Committee to the shareholders; (iii) the recommendations of the independent financial adviser; and (iv) a notice of EGM to approve among other things, the Perrigo Agreement and Eastwest Agreement and the respective annual caps, and to ratify the continuing connected transactions between the Company and Perrigo Company in 2007 and 2008, and between XPIE and Perrigo Company in 2007, will be dispatched to the Shareholders as soon as practicable.

E. DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

“Board”	the board of Directors
“Company”	山東新華製藥股份有限公司 (Shandong Xinhua Pharmaceutical Company Limited), a joint stock company incorporated in the PRC with limited liability
“Directors”	the directors of the Company
“Eastwest”	Eastwest United Group, Inc, a limited company established in the United States of America
“Eastwest Agreement”	the written agreement entered into between the Company and Eastwest dated 9 October 2008
“EGM”	The extraordinary general meeting of the Company to be held on 2008
“Hong Kong”	Hong Kong Special Administrative Region of the PRC
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Independent Board Committee”	the independent board committee of the Company constituted for the purpose of considering the Perrigo Agreement and Eastwest Agreement and the respective annual caps, and the continuing connected transactions between the Company and Perrigo Company in 2007 and 2008, and between XPIE and Perrigo Company in 2007, comprising three independent non-executive directors;
“L. Perrigo”	L. Perrigo Company, a company established in the United States.

“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Perrigo Agreement”	the written agreement entered into between the Company and Perrigo dated 7 October 2008
“Perrigo China Agreement”	the written agreement entered into between Xinhua Perrigo and Perrigo China Business Trust dated 3 July 2006
“Perrigo China Business Trust”	a trust created and organised under the laws of the PRC and [a subsidiary of] Perrigo Company
“Perrigo Company”	a company established in the United States
“Perrigo International”	Perrigo International, Inc., a company established in the United States and a wholly-named subsidiary of Perrigo Company
“PRC”	the People’s Republic of China
“RMB”	Renminbi, the lawful currency of the PRC
“Shareholders”	the shareholders of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Xinhua Eastwest”	淄博新華中西製藥有限責任公司 (Zibo Xinhua-Eastwest Pharmaceutical Company Limited), a PRC joint venture owned 75% by [the Company] and 25% by Eastwest.
“Xinhua Perrigo”	淄博新華-百利高製藥有限責任公司(SINO-USA Zibo Xinhua-Perrigo Pharmaceutical Company Limited), a PRC joint venture owned 50.1% by the Company and 49.9% by Perrigo International
“XPIE”	山東新華製藥進出口有限責任公司(Shandong Xinhua Pharmaceutical Import & Export Company Limited), a PRC limited company indirectly owned 98% by the Company
“Zibo”	Zibo City, situated in Shandong Province of the PRC

By Order of the Board
Shandong Xinhua Pharmaceutical Company Limited
Guo Qin
Chairman

23 October 2008, Zibo, PRC

As at the date of this announcement, the Board comprises:

Directors
Ms. Guo Qin (Chairman)
Mr. Liu Zhenwen
Mr. Ren Fulong
Mr. Zhao Songguo
Mr. Li Tianzhong

Independent non-executive Directors
Mr. Dai Qingjun
Mr. Xu Guojun
Mr. Sun Minggao